key: cord-0801506-axvonzvq
authors: Khashkhusha, Taqua R.; Chan, Jeffrey Shi Kai; Harky, Amer
title: ACE inhibitors and COVID‐19: We don't know yet
date: 2020-04-27
journal: J Card Surg
DOI: 10.1111/jocs.14582
sha: f72c9224f47b2be7c8ddb0db41d56d0000f2827f
doc_id: 801506
cord_uid: axvonzvq

nan

be upregulated in ACE inhibitors (ACEI) users. As ACEI are used extensively in the treatment of hypertension, there has been concern regarding the risk of using these medications in patients with COVID-19, and whether the use of such ACEI predisposes to Hypertension yet again was the most common comorbidity with 165 patients, followed by 81 patients with diabetes. A meta-analysis 3 evaluating the comorbidities associated with COVID-19 found similar results. These statistics raise the question of whether hypertension itself is a high-risk comorbidity or is the use of angiotensin-converting-enzyme inhibitor (ACEI) specifically as treatment responsible for these statistics. 

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Clinical characteristics of coronavirus disease 2019 in China

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis

Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension